NCT05100563

Brief Summary

High dose naltrexone with response gauged by pain tolerance as measured by the cold pressor test may help treat autism.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2018

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

October 22, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 24, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 24, 2021

Completed
5 months until next milestone

First Posted

Study publicly available on registry

October 29, 2021

Completed
Last Updated

May 11, 2022

Status Verified

November 1, 2020

Enrollment Period

2.6 years

First QC Date

October 22, 2020

Last Update Submit

May 10, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • improvement of social responsiveness scale (SRS) and social communication questionnaire (SCQ)

    evaluation by patient at baseline and follow up of SRS and his father SCQ

    After two weeks at optimal naltrexone dose

Secondary Outcomes (1)

  • Cold Pressor Time

    After a week on optimized naltrexone dose with repeat two weeks later

Interventions

Medication combined with twice a week psychotherapy

Eligibility Criteria

Age12 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adolescents and adults with autism spectrum disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Upstate Medical University

Syracuse, New York, 13210, United States

Location

MeSH Terms

Conditions

Autism Spectrum Disorder

Interventions

Naltrexone

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Intervention Hierarchy (Ancestors)

NaloxoneMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 22, 2020

First Posted

October 29, 2021

Study Start

October 1, 2018

Primary Completion

May 24, 2021

Study Completion

May 24, 2021

Last Updated

May 11, 2022

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations